Thermo Fisher Scientific announces expanded HLA-DQ coverage for more informed transplant decisions
Thermo Fisher Scientific introduces the LABScreen Single Antigen HLA Class II ExPlex Group 2, expanding HLA-DQ coverage for more comprehensive antibody assessment in transplant diagnostics, available in the EU under IVDR.
Thermo Fisher Scientific has expanded its LABScreen Single Antigen ExPlex Portfolio with the introduction of LABScreen Single Antigen human leukocyte antigen (HLA) Class II ExPlex – Group 2. The new panel extends HLA-DQ coverage, enabling more comprehensive antibody assessment in complex transplant cases.
Available now in the European Union under IVDR, the extended ExPlex panel can be combined in a single well with LABScreen Single Antigen assays — the established standard for HLA antibody detection — without requiring additional time after assay setup. Laboratories may gain expanded analytical capability without retraining staff, modifying workflows or investing in new instrumentation.
The expansion:
Adds 27 HLA-DQ antigens and heterodimers combinations to the existing 24-bead ExPlex offering
Creates anew51-bead extended panel
Enables assessment up to 146 Class II Single Antigen Beads in a single well
